NCCN Endorses Natera’s Signatera for Bladder Cancer Treatment Guidance
Event summary
- NCCN updated its bladder cancer guidelines to include ctDNA-MRD testing using Natera’s Signatera technology.
- The recommendation is based on evidence from the IMvigor011 trial, leading to a Category 1 designation for Signatera-guided adjuvant atezolizumab.
- Signatera CDx received FDA approval in May 2026 as a companion diagnostic for identifying MIBC patients who may benefit from adjuvant immunotherapy.
The big picture
The NCCN guideline update represents a significant validation for Natera’s Signatera technology, positioning it as a key tool in personalized cancer treatment. This shift toward MRD-guided care aligns with broader industry trends favoring precision oncology and could expand the market for Natera’s diagnostic offerings.
What we're watching
- Adoption Pace
- How quickly NCCN’s guideline update will drive clinical adoption of Signatera in bladder cancer treatment.
- Market Expansion
- Whether the success with bladder cancer will accelerate Signatera’s use in other cancer types.
- Competitive Response
- How competitors in the ctDNA-MRD space will react to NCCN’s endorsement of Signatera.
Related topics